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D
 PThe present work describes the drug:membrane interactions and a drug delivery system of the novel potent AT1blocker BV6. This designed analog has most of the pharmacological segments of losartan and an additional
biphenyltetrazole moiety resulting in increased lipophilicity. We found that BV6:membrane interactions lead
to compact bilayers that may in part explain its higher in vitro activity compared to losartan since such environ-
mentmay facilitate its approach to AT1 receptor. Its high docking score to AT1 receptor stems frommore hydro-
phobic interactions compared to losartan. X-ray powder diffraction (XRPD) and thermogravimetric analysis
(TGA) have shown that BV6 has a crystalline form that is not decomposed completely up to 600 °C. These prop-
erties are desirable for a drug molecule. BV6 can also be incorporated into a mesoporous silicate drug-delivery
matrix SBA-15. The properties of the obtained drug-delivery system have been inspected by XRD, 13C CP/MAS,
TGA and nitrogen sorption experiments.
© 2013 Published by Elsevier B.V.378C
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1. Introduction
Coronary heart disease is one of the leading causes of death in the
industrialized world. Hypertension is a risk factor for cardiovascular
disease (CV) and is associated with an increased incidence of stroke
and coronary heart disease. Other risk factors for CV include also
high cholesterol, diabetes and obesity. Although there have been
many advances in treatment over the past several decades, less than
a quarter of all hypertensive patients have their blood pressure ade-
quately controlled with available therapies. Early management of
cardiovascular risk factors is fundamental in preventing the develop-
ment of cardiovascular and renal disease [1,2].
The renin–angiotensin system (RAS) is known to play an important
role in the regulation of blood pressure and electrolyte balance. Inhibi-
tors of the RAS would be effective for the treatment of hypertension
and congestive heart failure. Although angiotensin-converting enzyme
(ACE) inhibitors are highly effective and their use has become well-
established for the treatment of hypertension and congestive heart
failure, they suffer from some side effects such as dry cough and78
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actions of the potent syntheti
13), http://dx.doi.org/10.1016angioedema caused by the nonspeciﬁc action of ACE. On the other
hand, angiotensin II (AII) AT1 receptor blockers (ARBs) selectively in-
terfere with the RAS at the AII receptor level and are expected to be
more speciﬁc and effective agents than ACE inhibitors. The discovery
of potent and orally active non peptide AII antagonists such as losartan
and eprosartan has encouraged the development of a large number of
similar compounds. Among them, candesartan cilexetil, valsartan,
irbesartan, telmisartan and olmesartanmedoxomil have been launched
and were established as angiotensin receptor blockers (ARBs). Treat-
ment with an ARB was demonstrated to reduce CV events and heart
failure progression as well as to improve renal disease and prevent dia-
betes and this constitutes the importance of their development. Despite
the plethora of treatment options for themanagement of hypertension,
55.9% of patients do not have their BP under adequate control. In addi-
tion, there is ambiguity concerning the appropriate choice of therapy for
hypertensive patientswhomay presentwith coexisting conditions such
as diabetes. Therefore, an agent with multifunctional purposes would
offer an efﬁcacious way of managing hypertension and related compli-
cations. Azilsartan medoxomil is a newer-generation ARB with potent
antihypertensive effects. On 25 February 2011, the U.S. Food and Drug
Administration (FDA) approved azilsartan medoxomil for the treat-
ment of high blood pressure in adults [3–5].
The molecular basis of their antihypertensive action has been
interpreted by a two-step model. In the ﬁrst step they are incorporat-
ed into the bilayers through the lipid–water interface and secondlyc AT1 antagonist analog BV6withmembrane bilayers andmesoporous
/j.bbamem.2013.03.009
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2 G. Agelis et al. / Biochimica et Biophysica Acta xxx (2013) xxx–xxxlaterally diffuse to reach the active site of the AT1 receptor in order to
exert their biological activity [6].
BV6 (4-butyl-Ν,Ν -bis{[2 -(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}
imidazolium bromide) is a synthetic rationally designed molecule that
exhibited higher activity than losartan (Fig. 1). Thismolecule comprises
three well known pharmacophore segments identical to losartan, in
particular the two biphenyltetrazole segments at the N-1 and N-3 of
the imidazole ring and the butyl alkyl chain. However, it lacks the chlo-
rine atom and hydroxymethyl group on the imidazole ring. Its higher
activity can be postulated to be attributed to: (a) the way it interacts
on the lipid bilayer as it is amore lipophilic entity; (b) the additional hy-
drophobic interactions that can be had at the active site of the receptor
(Fig. 2) [7]. Estimated value of LogP for BV6 byALOGPS 2.1 programwas
found to be 5.70 (for comparison reasons LogP of losartan was found to
be 4.50) [8]. LogP values for all commercial sartans are given in Table 1.
BV6 has the highest LogP value after telmisartan.
The cellular membranes are complex entities consisting of various
kinds of proteins and lipids as well as cholesterol. Phosphatidylcholines
(PCs) are the most abundant lipid species in sarcolemma cardiac
membranes [9]. The most frequently found among them are PCs withU
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Fig. 1. Chemical structures of BV6 and L
Please cite this article as: G. Agelis, et al., Interactions of the potent syntheti
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F
oleic and linoleic chains, and further dipalmitoylphosphatidylcholine
(DPPC). Experimentally, hydrated DPPC lipids are preferred because
they spontaneously formmultilamellar bilayers in whichmesomorphic
changes occur in a convenient temperature range between 25 and
50 °C. Their dynamic and thermotropic properties have been extensive-
ly explored [10–12] and their partition coefﬁcient especially in the ﬂuid
state, resembles that of natural cardiac membranes [9]. Phosphatidyl
choline bilayers at low temperatures occur in the gel phase (Lβ′) and
at higher temperatures in the liquid-crystalline phase (Lα). The transi-
tion is accompanied by several structural changes in the lipidmolecules
aswell as systematic alteration in the bilayer geometry, for example the
trans:gauche isomerization taking place in the acyl conformation. The
average number of gauche conformers indicates the effective ﬂuidity,
which depends not only on the temperature, but also on perturbation
due to the presence of a drugmolecule intercalating between the lipids.
It is more and more evident that drugs affect the lipid core and
form microdomains that modulate the activity of the vicinity of pro-
teins and thus offer a new avenue in the membrane lipid therapy. A
representative example is the drug:membrane interactions of the
β2 agonists indacaterol and salmaterol which are characterized byE
D
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R
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α-dipalmitoylphosphatidylcholine.
c AT1 antagonist analog BV6withmembrane bilayers andmesoporous
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Fig. 2. Hydrophobic interactions of A. BV6 and B. losartan in the active site of AT1 receptor.
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different pharmacological properties. It was found that the synergy
between the higher partitioning of indacaterol into the raft micro do-
mains and the faster membrane permeation of indacaterol could ex-
plain the faster onset and longer duration of therapeutic effect of
indacaterol. The higher ﬂuidizing effect of salmeterol on membrane
ﬂuidity may contribute to its lower intrinsic efﬁcacy compared to
indacaterol [13]. Other studies postulated that active drugs do change
the lateral pressure proﬁle in bilayers and hence, can affect the behav-
ior of membrane proteins [1–6,9–16]. As a consequence of this, every
bioactive molecule has its special ﬁngerprint when it interacts with
membrane bilayers [17].
In this context, our laboratory has initiated research activity to
study the effects of ARBs losartan, valsartan, olmesartan, CV-11974
and TCV-116 in membrane bilayers [18–21]. Thus, the signiﬁcant
amount of work performed on AT1 receptor blockers could also
serve for comparative studies and further elaborate on the role of
the drug in the cell membrane. In this study, the effects of the syn-
thetic BV6 molecule intercalated in DPPC membranes were investi-
gated and then were compared with the commercial ARB drugs.
An integrated approach using different complementary methodol-
ogies namely solid state 13C CP/MAS and 13C MAS NMR spectroscopy,
HR-NMR spectroscopy, Differential Scanning Calorimetry (DSC),
Raman spectroscopy, have been applied. Brieﬂy, DSC provides valu-
able information on the thermal modiﬁcations that are caused by
the presence of drugs in the membrane [22]. Solid state NMR experi-
ments offer useful information about the dynamic changes that drugs
cause when they are incorporated in the lipid bilayers [22–25]. Typi-
cal observations are related with chemical shift or intensity changesU 180181
182
183
184
Table 1t1:1
t1:2 LogP values of BV6 and AT1 antagonists calculated
t1:3 by ALOGPS 2.1 program [8].
t1:4 Compounds LogP
t1:5 BV6 5.70
t1:6 Losartan 4.50
t1:7 Candesartan 4.02
t1:8 Irbesartan 4.51
t1:9 Valsartan 3.68
t1:10 Olmesartan 1.79
t1:11 Azilsartan 4.50
t1:12 Telmisartan 6.66
t1:13 Tasosartan 3.07
Please cite this article as: G. Agelis, et al., Interactions of the potent syntheti
silicate matrices, Biochim. Biophys. Acta (2013), http://dx.doi.org/10.1016E
D
 Pof various key atoms which are partitioning in the membrane. Chem-ical shift changes are further associated with phase transition proper-ties of the membrane bilayers. Moreover new peaks arise due to the
presence of the drug. Raman experiments provide complementary
structural information, for instance regarding the interdigitation ef-
fects of the molecules in lipid bilayers [26–28].
In the last part of themanuscriptwediscuss the solid (powder) form
of BV6, and the drug-delivery system prepared from BV6 and the
mesoporous silicate matrix SBA-15 [29]. The role of silicate-based
drug-delivery systems in the transport of drugs through cell mem-
branes has not been explored yet. Rather, the silicate-based drug-
delivery systems were studied either to improve the availability of the
drugs that are poorly soluble in physiological media or to enable con-
trolled release of drugs in the body [30]. Since BV6 itself is well soluble
in water-rich media, the main purpose of incorporating it into the
mesoporous silicate matrix would be to gain control over the rate of
the drug release (for example, to achieve prolonged release of the
drug) or to gain control over the location of the drug release. On the in-
ternal and external surface, mesoporous silicates possess a signiﬁcant
amount of free silanol groups, which can be functionalized [31]. The
attached functional groups can change physico-chemical properties of
the surface and can therefore lead to speciﬁc interactions of the phar-
maceutical system with the target environment or with the external
stimuli. Some examples of functionalized mesoporous silicates used as
matrices for site-speciﬁc or/and stimuli-responsive drug delivery in-
clude a polyamine-functionalized mesoporous silicate that releases
drug only in neutral medium and not in the acidic one [32], SBA-15
functionalized with carboxylic groups that allow release of drugs only
in acidic medium [33], and mesoporous silicate functionalized with
superparamagnetic Fe3O4 nanoparticles, because ofwhich the transport
of drug-delivery particles within a body could be directed by external
magnetic ﬁelds [34]. In this contribution we study only the possibility
of the incorporation of BV6 into themesoporous silicate SBA-15matrix.185
186
187
188
1892. Material and methods
2.1. Drug:membrane interaction system
2.1.1. Differential Scanning Calorimetry
To prepare the samples for DSC experiments, appropriate amounts
of DPPC and BV6 diluted in chloroform were mixed, dried underc AT1 antagonist analog BV6withmembrane bilayers andmesoporous
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stream of argon and then stored under high vacuum overnight. Dis-
tilled and deionized water was added to the dried mixtures of
DPPC–BV6 to produce a 50% (w/w) mixture/water preparation. The
samples were transferred to stainless steel capsules obtained from
Perkin-Elmer and sealed. Thermal scans were obtained on a Perkin-
Elmer DSC-2 instrument (Norwalk, CT). All samples were scanned
from 10 to 60 °C at least three times until identical thermal scans
were obtained using a scanning rate of 2.5 °C/min. The temperature
scale of the calorimeter was calibrated using indium (Tm = 156.6 °C)
and DPPC bilayers (Tm = 41.2 °C).
The following diagnostic parameters were used for the study of drug
tomembrane interactions: Tm (maximum position of the recorded heat
capacity), Tonset (the starting temperature of the phase transition) and
ΔTm1/2 (the full width at half maximum of the phase transition), and
the respective parameters concerning the pre-transition. An empty
pan for the base line and a sample containing double distilled water
were run for the temperature range of 10–60 °C as a reference for the
background. This background was subtracted from each thermal scan
of the samples. The area under the peak, represents the enthalpy change
during the transition (ΔΗ). The mean values of ΔΗ of three identical
scans were tabulated. The drug concentration used for the different ex-
periments was x = 0.20 (20 mol% BV6).
2.1.2. Raman spectroscopy
Raman spectra were recorded with a Perkin-Elmer GX Fourier
Transform spectrometer (Shelton, CT). A diode pumped Nd:YAG laser
at 1064 nm (Norwalk, CT) was used as the excitation source. The
scattered radiation was collected at an angle of 180° with respect to
the incident beam. Spectra were recorded at a laser power of 400 mW
on sample with a resolution of 2 cm−1. To obtain a good signal-
to-noise ratio, 2500 scanswere coadded for each spectrum. The temper-
ature was controlled using the high-temperature cell (CAL 3300,
Ventacon Ltd., Winchester, UK). The intensity of a Raman band was ob-
served over a period of 15 min. Analysis of the spectra was carried out
using Spectrum Software Version No. 3.02.01 (Perkin-Elmer, Norwalk,
CT). Raman spectra of the examined samples were obtained in the fre-
quency region of 3500–400 cm−1 and in the temperature range 25 to
50 °C. The following ratios as a function of temperature were used for
the study of drug to membrane interactions: I1090/I1130.: This ratio al-
lows the direct comparison of the bilayer disorder–order characteristics
between bilayers preparations without or with drug incorporation
[26,27]. I2935/I2880: This ratio measures the effects originating from
changes both in interchain and intrachain order–disorder processes in
the bilayer acyl chains. I2850/I2880: This ratio describes the main change
occurring in the hydrocarbon-chain region of the lipids and corresponds
to intermolecular interactions among aliphatic chains.
2.1.3. High resolution liquid and solid state NMR
The high-resolution NMR spectra were recorded on a Varian
800 MHz spectrometer at 25 °C. Spectra were obtained with 2 mg
of sample dissolved in 0.7 ml CD3OD (Sigma Aldrich, St. Louis, MO).
Default parameters installed in the library of the spectrometer were
used. The 1H and 13C chemical shift assignments were obtained in a
standard way using DQF-COSY, HSQC, and HMBC 2D experiments.
Spectra were collected in the phase sensitive mode using the pulse
sequences in the Varian library of pulse programs. Spectra allowed
the unambiguous assignment of BV6.
The procedure to prepare the samples for 13C MAS and 13C CP/MAS
spectroscopy was identical to that applied for DSC samples. Brieﬂy,
distilled and deionized water was added to the dried binary mixtures
of DPPC/BV6 to produce a 50% (w/w) liposome dispersion. The samples
were transferred to 3.2 mm zirconia rotors. 13C NMR spectra were
obtained at 150.80 MHz with a 600 MHz Varian spectrometer (Palo
Alto, CA). The spinning rate used was 5 kHz. The experimental temper-
atures were 25 °C, 35 °C, and 45 °C for 13C CP/MAS experiments and
45 °C for the 13C MAS measurement.Please cite this article as: G. Agelis, et al., Interactions of the potent syntheti
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2.2. Drug-delivery systems
BV6 was incorporated into the mesoporous silicate SBA-15 matrix.
SBA-15 was synthesized according to Sayari et al. [35] using structure
directing agent Pluronic P123 (PEG–PPG–PEG block copolymer,
Aldrich) and tetraethyl orthosilicate (98% TEOS, Aldrich) as a silica
source. Drug-loading procedure started by dissolving 70 mg of BV6 in
1 g of dimethyl sulfoxide (DMSO). The solution was added dropwise
to ﬁne layer of calcined SBA-15, allowing the powder to soak up the
added drops. The obtained sample was then dried using a two step dry-
ing procedure combining drying at 313 K for 24 h in a ventilation dryer
followed by drying at 313 K for 24 h in a vacuum dryer. The obtained
composite was denoted as SBA-15/BV6.
2.2.1. X-ray powder diffraction (XRPD)
XRPD patterns of solid samples were recorded on a PANalytical
X'Pert PRO high-resolution diffractometer using CuKα1 radiation
(1.5406 Å) in the 2θ range between 5° and 35°, taking 100 s for a
step of 0.033°. For the SBA-15/BV6 composite XRPD pattern was
recorded also in the 2θ range between 0.5° and 5°.
2.2.2. Thermogravimetric analysis (TG)
Thermogravimetric analyses (TG) were carried out between 298 K
and 873 K with a heating rate of 20 K/min using Mettler Toledo
(Schwerzenbach, Switzerland) thermo-gravimetric analyzer model
TGA/DSC 1 under a constant gas ﬂow rate (oxygen, 50 mL/min). The
initial sample masses ranged between 3 and 5 mg.
2.2.3. Nitrogen adsorption–desorption measurement
Adsorption and desorption isotherms of nitrogen were measured
on a Micromeritics ASAP 2020 volumetric adsorption analyzer at
77 K. Before the sorption analysis, SBA-15 and SBA-15/BV6 samples
were outgassed under vacuum for 4 h at 373 K. The BET speciﬁc sur-
face areas (SBET) were estimated using adsorption data in the relative
pressure range between 0.05 and 0.22 for SBA-15 and between 0.03
and 0.24 for SBA-15/BV6. The total pore volumes (Vt) for the empty
matrix and for the drug-delivery system were estimated from the
amounts of nitrogen adsorbed at relative pressures of 0.953 and
0.943, respectively, converting them to the volumes of liquid nitrogen
at 77 K. The microporosity (Vmi) was determined by the t-plot method.
The pore size distribution was obtained by analyzing the adsorption
data of the sorption isotherm using the DFT approach.
2.2.4. 13C CP/MAS NMR spectroscopy
13C CP/MAS NMR spectra were recorded on a 600 MHz Varian
NMR System equipped with a 3.2 mm Varian MAS probehead. Larmor
frequency for 13C nuclei was 150.812 MHz, relaxation delay was 5 s, CP
contact time was 5 ms, and sample rotation frequency was 16 kHz.
Chemical shift was reported relative to the signal of 13C nuclei in
tetramethylsilane.
3. Results
3.1. Drug:membrane interactions
3.1.1. Differential Scanning Calorimetry
In previous studies we used Differential Scanning Calorimetry to
detect the thermal changes caused by AT1 receptor blockers when
they are incorporated in the lipid bilayers. We found out that x =
0.20 was the most critical to detect differential effects. For this reason,
we have chosen this concentration as a representative for comparison
with other AT1 receptor blockers already studied. The DSC results
shown in Fig. 3 revealed that BV6 causes enhancing of the bilayer
packing shifting the Tm from 42.2 °C to the higher value of 43.81 °C
(the corresponding Tonset for the bilayer with and without BV6 were
42.49 °C and 40.91 °C) and caused increase in ΔΗ (7.98 kcal/molc AT1 antagonist analog BV6withmembrane bilayers andmesoporous
/j.bbamem.2013.03.009
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3.1.2. Raman spectroscopy
The methylene C\H stretching mode region 2800–3100 cm−1
provides the most intense bands in the Raman spectrum of lipid sam-
ples and is commonly used to monitor changes in the lateral packing
properties and mobility of the lipid chain in both gel and liquid crys-
talline bilayer systems. In particular, the intensity ratio I2850/I2880 pro-
vides an order parameter of the bilayer core. Indeed, this ratio
indicates that bilayers with incorporated BV6 are more ordered than
pure DPPC bilayers in accordance with DSC data (see Fig. 4A).
The C\C stretching mode region in the 1050–1150 cm−1 spectral
interval reﬂects directly intramolecular trans:gauche conformational
changes within the hydrocarbon chain region of the lipid matrix.
More importantly, the temperature proﬁles of the peak height intensity
ratio I1090/1130 allows the direct comparison of the bilayer disorder–
order characteristics between bilayer preparations without or with
BV6. BV6 induces lowering of gauche:trans ratio (see Fig. 4B).
The peak height intensity I2935/I2880 ratio constitutes a sensitive
probe to monitor the lipid phase transitions despite the fact that the
C\H stretching mode region consists of many superimposed vibra-
tional transitions. Fig. 4C shows changes in I2935/I2880 peak height in-
tensity ratio caused by BV6, when incorporated in DPPC bilayers.
DPPC bilayers alone and those containing BV6 resemble the corre-
sponding ones of the ratio I1090/I1130.
Various other bands are examined (not shown). For example the band
at 714 cm−1 is shifted to 717 cm−1 showing strong interaction of BV6
with polar region. Bands corresponding to\CH3 or\CH2 were not sig-
niﬁcantly affected. The bands at 1600 cm−1 and 1620 cm−1 which cor-
respond to the asymmetric and symmetric stretch vibrations of the
C_C bonds clearly conﬁrm the incorporation of BV6 in the lipid
bilayers.353
354
355
356
357
Temperature (oC)
Fig. 4. (A) I2850/I2880 vs. temperature plots for pure DPPC (squares), DPPC containing
x = 0.20 of BV6 (circles). With the same symbolic meaning as in panel A vs. tempera-
ture plots (B) I1090/I1130 and (C) I2935/I2880 are depicted. Q23.1.3. 13C MAS and CP/MAS NMR spectroscopy
We have applied high-resolution NMR spectroscopy using magic
angle spinning without or with cross polarization to obtain detailed
local information on the incorporation of BV6 in the DPPC bilayers.
Each spectrum was divided into three regions, namely concerning
the carbon atoms in the (i) hydrophobic region (10–40 ppm), those
in (ii) head-group, glycerol backbone regions and region containing
carbons between aromatic segments (55–80 ppm) and (iii) aromatic
and esteriﬁed carbonyls (125–180 ppm) (see Fig. 5).Please cite this article as: G. Agelis, et al., Interactions of the potent syntheti
silicate matrices, Biochim. Biophys. Acta (2013), http://dx.doi.org/10.10163.1.3.1. Hydrophobic region. The chemical shift decreases (upﬁeld effect),
when DPPC bilayers undergo the transition from the lamellar gel phase
Lβ′ (25 °C) towards the ripple phase Pβ′ (35 °C) and lamellar liquid crys-
talline phase Lα (45 °C) (see Table 2 and Fig. 6). This is due to the strong
trans:gauche isomerization effects observed especially in the turnover toc AT1 antagonist analog BV6withmembrane bilayers andmesoporous
/j.bbamem.2013.03.009
TF
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
T = 45oC
T = 35oC
T = 25oC
ppm
DPPC
DPPC+ BV6
DPPC
DPPC+ BV6
DPPC
DPPC+ BV6
35 30 25 20 1570 65 60 55170 160 150 140 130
Fig. 5. 13C NMR CP/MAS spectra of DPPC bilayers with and without BV6 at three temperatures covering all the mesomorphic states of the lipid bilayers.
t2:1
t2:2
t2:3
t2:4
t2:5
t2:6
t2:7
t2:8
t2:9
t2:10
t2:11
t2:12
t2:13
t2:14
t2:15
6 G. Agelis et al. / Biochimica et Biophysica Acta xxx (2013) xxx–xxxthe Lα phase. For example, we detected an upﬁeld change between 0.2
and 2.2 ppm for (CH2)′10, C-14′, C-15′ and C-16′ signifying the same
trend and different extent of upﬁeld effect of the carbons that constitute
the hydrophobic region. Upﬁeld effect (0.1–2.3 ppm) was also observed
in DPPC/BV6 bilayers. Generally, at the same temperature the values for
samples containing BV6 were slightly higher.
A peak at ca 15 ppm was observed which is attributed to the ter-
minal carbon of the methyl group (C9) of the butyl alkyl chain of BV6
as was elucidated using a combination of 1D and 2D NMR spectra (not
shown). Approximately at 25 ppm an eminent additional peak is
attributed to C8 of the alkyl chain. Several peaks of small intensity
have been observed in the aromatic region. To examine the effect of
cross polarization we have run the same experiments at 45 °C using
MAS without applying cross polarization. Indeed all additional peaks
were also observed in MAS experiment (Fig. 6).
3.1.3.2. Head-group, glycerol backbone regions and region containing car-
bons between aromatic segments. Smaller chemical shift changes were ob-
served for the two preparations used in our experiments indicating thatU
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Table 2
Observed chemical shifts for DPPC carbons in 13C MAS and 13C CP/MAS experiments.
13C MAS
C-X
T
(°C)
Sample C-1 C-2 C-3 C-1′,
C-1″
C-2′,
C-2″
C-3′,
C-3″
(C
(C
DPPC 63.80 71.41 64.41 174.02 34.81 25.86 3
45 DPPC/BV6 63.90 71.53 64.54 174.15 34.86 25.79 3
13C /MAS
DPPC – 71.22 64.38 172−175 34.98 26.72 3
25 DPPC/BV6 – 71.54 64.71 173.95–175.55 – 26.77 3
DPPC – 71.14 64.38 172–175 35.10 26.37 3
35 DPPC/BV6 – 71.55 64.61 173.83–174.48 35.19 26.48 3
DPPC 63.77 71.37 64.49 174.03 34.81 25.85 3
45 DPPC/BV6 – 71.60 64.58 174.27 – 25.85 3
DPPC
DPPC+ BV6
70 65 60170    160 140 130150
Fig. 6. 13C NMR MAS spectra of DPPC bila
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Ohead-group conformational changes from gel to liquid crystalline phaseare less pronounced compared to that observed in the hydrophobic re-
gion (Table 2). Speciﬁcally, a downﬁeld shift (b0.2 ppm) was observed
during the phase transition from the gel to liquid crystalline state for
the two preparations for the carbons of the head-group indicating as is
already mentioned its conformational stability in this bilayer region.
Steadily, as in the hydrophobic region the preparation containing BV6
had a slighter higher chemical shift than the pure DPPC bilayers.
An additional peak close to 55 ppm is observed which corre-
sponds to C10′ methylene group of BV6. This was also observed in
MAS experiments.
3.1.4. Aromatic and carbonyl regions
Only at 45 °C the aromatic region of BV6 is eminent but still con-
tains low intensity peaks. To test if this is due to inefﬁcient cross po-
larization we observed the corresponding MAS spectra. Clearly, in the
MAS spectra these peaks are still of low intensity signifying the fact
that their low intensity is attributed to rigidity of the bilayers when
BV6 is incorporated rather than inefﬁcient cross polarization.H2)′10,
H2)″10
C-14′,
C-14″
C-15′,
C-15″
C-16′,
C16″
N(CH3)3 C-2‴ C-1‴
1.10 32.83 23.41 14.49 54.89 66.82 60.21
1.09 (+3 shoulders) 32.91
33.12
23.48 14.58 54.95 66.91 60.32
3.25 34.22 24.45 14.65 54.76 66.63 60.22
3.35 – 24.26
+24.55
14.67 54.86 66.78 60.35
3.11 – 24.25 14.60 54.79 66.69 60.20
3.25 – 24.10
+24.39
14.65
+14.99
54.91 66.83 60.34
1.06 32.79 23.39 14.49 54.86 66.81 60.19
1.08+33.27 – 23.58 14.80 54.90 66.91 60.35
T = 45oC
ppm35 30 25 20 1555
yers with and without BV6 at 45 °C.
c AT1 antagonist analog BV6withmembrane bilayers andmesoporous
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Fig. 7. XRPD patterns (A) and 13C CP/MAS NMR spectra (B) of the bulk substance BV6
and of the drug-delivery system SBA-15/BV6. Plot (B) contains tentative assignment of
13C CP/MAS NMR signals to carbon atoms within BV6. The numbers above the horizon-
tal lines correspond to carbon-atom labels as used in Fig. 1.
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The resolution of C-1′ in the carbonyl region for the two preparations
was not satisfactory to follow the chemical shift changes during the
phase transition. However, from the shape of the peaks it can be
realized that DPPC bilayers containing BV6 are more rigid compared
to the pure DPPC bilayers.
3.2. Analysis of the solid form and of the drug-delivery system
X-ray diffraction pattern of the powdered BV6 (Fig. 7A) exhibits
sharp diffraction peaks and shows that the neutral substance is a crystal-
line material. The 13C CP/MAS NMR spectrum (Fig. 7B) also exhibits rel-
atively narrow lines, which, however, overlap substantially so that the
contributions from the various carbon sites cannot be easily resolved.
(A tentative assignment of the resonances is presented in Fig. 7B.) Car-
bon signals resonating at about 160 ppm can be assigned to carbon
atomsof the tetrazole rings of BV6. It seems that the packing of BV6mol-
ecules within the crystals is such that either the two carbon sites within
the two tetrazole rings of the same molecule experience slightly differ-
ent environments or that two (crystallographically inequivalent) BV6
molecules comprise the crystallographic asymmetric unit.
The diffraction pattern of the drug-delivery system obtained after
the incorporation of BV6 into the mesopores of SBA-15 exhibits dif-
fraction peaks only in the range between 0.5° and 2°. These peaks
are characteristic for the ordered hexagonal arrangement of the
mesopores of the silicate matrix [29]. Obviously, the BV6 molecules
are too large and the pores of SBA-15 with the diameter of approxi-
mately 11 nm are too narrow that (sufﬁciently large) crystallites,
which would give rise to narrow diffraction maxima at higher diffrac-
tion angles, could be formed. As opposed to the diffraction maxima,
the signals within the 13C CP/MAS NMR spectrum of BV6 within the
delivery system are still clearly visible and only slightly broader
from the signals of the bulk crystalline substance. A new narrow sig-
nal at about 40 ppm belongs to the trace of solvent. Apparently the
drying procedure leaves traces of DMSO molecules within the pores.
The spectra of the powdered BV6 and the BV6 incorporated within
SBA-15 both exhibit two resolved signals of the tetrazole carbon nu-
clei. Since the packing of the neutral BV6 molecules within the
pores of SBA-15 is most probably different from the packing of
these molecules within the pure crystals, the two slightly different
environments for carbon nuclei within the two tetrazole rings must
stem from the asymmetry of a BV6 molecule alone and do not belong
to carbon nuclei from two separate BV6 molecules.
The crystalline BV6 and the drug-delivery system based on the sub-
stance were submitted also to thermogravimetric analysis (Fig. 8).
Somewhat surprisingly, in the temperature range between 25 °C and
600 °C BV6 was not entirely decomposed. This is most probably due
to the fact that BV6 is actually a salt and salts typically exhibit very
highmelting points. For the drug-delivery system the loss ofmasswith-
in the above mentioned temperature interval was even smaller, which
is understandable, knowing that the silicate mesoporous matrix is
completely stable up to 600 °C [29] and that the observed mass
loss was only due to the (partial) removal of the drug from the pores
of the drug-delivery system. If the reduction of the mass of drug within
the delivery system is comparable to the reduction of the mass of drug
in the bulk form, then the initial mass fractionm(BV6)/m(SBA-15/BV6)
can be estimated to be approximately 0.55. This fraction is quite high
and exceeds the one that was observed for the drug-delivery systems
in which indomethacin was incorporated into SBA-15 [36,37]. If, how-
ever, up to 600 °C all the drug is expelled from the pores of the matrix,
then the initial mass fractionm(BV6)/m(SBA-15/BV6) can be estimated
to be approximately 0.35.
To gain some additional insight into the prepared drug delivery
system, ﬁnally, SBA-15/BV6 and the parent SBA-15 material were
subjected to the nitrogen sorption analysis. This analysis is an important
approach for the inspection of the porosity of the materials. The
measured adsorption–desorption isotherms and the derived pore-sizePlease cite this article as: G. Agelis, et al., Interactions of the potent syntheti
silicate matrices, Biochim. Biophys. Acta (2013), http://dx.doi.org/10.1016distribution proﬁles are presented in Fig. 9 and the quantitative data on
the speciﬁc surface area and pore volume of the two materials are listed
in Table 3. In the ﬁgure we can see that both nitrogen adsorption–
desorption isotherms are of type IV sorption isotherms according to
the IUPAC classiﬁcation and exhibit well-deﬁned H1 hysteresis loops,
which are typical for SBA-15 silicates. The presence of H1 hysteresisc AT1 antagonist analog BV6withmembrane bilayers andmesoporous
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Table 3 t3:1
t3:2Speciﬁc surface areas and pore volumes of SBA-15 and SBA-15/BV6 samples.
t3:3Sample SBET (m2/g) Vt (cm3/g) Vmi (cm3/g)
t3:4SBA-15 662 0.90 0.07
t3:5SBA-15/BV6 197 0.33 0.02
Fig. 8. TG proﬁles of the bulk BV6 and of the drug-delivery system SBA-15/BV6.
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type conﬁrms that the parent material and the drug-delivery system
have open-ended cylindrical mesopores. One can also see that after
the impregnation of the mesoporous silicate matrix with the BV6 drug,
the pore volume and the speciﬁc surface area was reduced drastically —
to approximately one third of the initial value. This is an indication that
indeed a substantial amount of the drug was incorporated into the
pores of SBA-15.
4. Discussion
4.1. DSC
The incorporated BV-6 in lipid bilayers exerts similarities and dif-
ferences in thermal effects when these are compared with those
exerted by the commercial AT1 receptor blockers. The similarities
are expressed in: (a) abolishment of the pre-transition; (b) increase
of the breadth of the phase transition and (c) increase of ΔΗ. Howev-
er, BV6 is the only active AT1 antagonist studied so far that causes also
increase in Tm probably due to the fact that augments hydrophobic
interactions when it is embedded in the lipid bilayers. This favored
packing of lipid bilayers when BV6 is intercalated may explain its
suitable ﬁt in the core of the lipid bilayers and easy approach at the
AT1 active site resulting in high in vitro activity.
4.2. Raman spectroscopy
The decrease of the mobility and gauche:trans ratio observed in
the Raman spectroscopy is in agreement with DSC results which
show that BV6 strengthens the packing of the lipid bilayers. Also in
the ratio of I2935/I2880 a shift was observed in higher temperatures
in accordance with DSC results. The strong inter actions observed
for BV6 with head-group were in accordance with DSC resultsU
N
C
Fig. 9. Nitrogen sorption isotherms (A) and pore siz
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where an abolishment of pre-transition was observed. The direct in-
corporation of BV6 in lipid core was observed by detecting C_C vi-
bration stretches in the region of 1600–1620 cm−1. This is again in
harmony with DSC results which showed a differential thermal scan
proﬁle of the bilayer containing BV6 in comparison with DPPC bilay-
ers without the drug. The ratio I2850/I2880 is considered also to be di-
agnostic for interdigitation effects. As with most of the commercial
AT1 antagonists, BV-6 appears to cause interdigitation effects in ac-
cordance with DSC data which showed increase of ΔΗ and Tm.
4.3. Solid state 13C CP/MAS and 13C MAS
In our previous studies we have observed that intensities in the aro-
matic region depend on the rigidity of the system.When prototype AT1
receptor blocker was incorporated in DPPC bilayers we were able to
structurally elucidate all the peaks attributed to the aromatic region [6].
This was not observed however in the case of DPPC bilayers
containing olmesartan where the aromatic region is more extended
[19]. In the case of BV6, the aromatic region is even more extended
and this leads to even more rigid system. Makriyannis et al observed
an identical relationship between GPCR cannabinoid agonists that
act on the head-group vicinity as it is recently reported by using
solid state 2H NMR spectroscopy. More speciﬁcally, the more rigid
Δ8-tetrahydrocannabinol compared with CP-55940 (synthesized
by Pﬁzer) andWIN-55212-2 (discovered by the SterlingWinthrop re-
search team) increased to a greater degree the order parameter of the
bilayer core [38].
4.4. Solid form and drug-delivery system
XRD and NMR analyses showed that the solid form of BV6 is crys-
talline. The substance probably shows crystalline structure because it
is a salt, in which the positive charge on the imidazole ring is neutral-
ized by the Br− anion. Of course, salts are usually substances that
crystallize easily.
BV6 could be incorporated into the mesopores of the mesoporous
silicate matrix SBA-15 with a high ﬁlling fraction. The incorporated
substance resembles amorphous materials. Taking into account that
the chemical shifts for the bulk substance and the substance embed-
ded within the mesopores are almost the same, BV6 molecules most
probably interact with the silicate walls very weakly. Of course, thee distributions (B) of SBA-15 and SBA-15/BV6.
c AT1 antagonist analog BV6withmembrane bilayers andmesoporous
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interaction, which eventually inﬂuences the drug-release rate, could
be altered by the functionalization of the mesoporous silicate matrix.
5. Conclusions
We have studied the drug:membrane interactions and drug-delivery
system of a novel synthetic AT1 antagonist BV6 that possesses higher in
vitro activity than prototype drug in sartan class losartan. Although it has
almost all pharmacophoric segments of losartan, the novel analog BV6 is
bulkier and more lipophilic. Its high lipophilicity in conjunction with
its amphiphilic properties constitutes the driving force for its intercala-
tion in the lipid bilayers and increase of their packing abilities. These
properties are observed also with commercial AT1 antagonists but to
a lesser extent. Since BV6 has these desirable properties in the lipid bi-
layers that may explain in part its diffusion ability to the AT1 receptor
and its favorable binding, we found it interesting to investigate its
physico-chemical and delivery properties in SBA-15 system. Its crystal-
line properties and especially high stability in decomposition are highly
desirable properties for a drug. Its size and shape allow its packing into
the delivery SBA-15 system with a relatively high efﬁciency.
Acknowledgement
This research has been coﬁnanced by the Slovenian Research
Agency (program P1-0021), and by the European Union (European
Social Fund—ESF) and Greek national funds through the Operational
Program “Education and Lifelong Learning” of the National Strategic
Reference Framework (NSRF)-Research Funding Program: Heracleitus
II, investing in knowledge society through the European Social Fund.
Darja Maučec and Emanuela Žunkovič are acknowledged for their
help with nitrogen sorption analysis.
References
[1] P. Verdecchia, F. Angeli, S. Repaci, G. Mazzotta, G. Gentile, G. Reboldi, Comparative
assessment of angiotensin receptor blockers in different clinical settings, Vasc.
Health Risk Manag. 5 (2009) 939–948.
[2] J.M. Neutel, Choosing among renin–angiotensin system blockers for the manage-
ment of hypertension from pharmacology to clinical efﬁcacy, Curr. Med. Res.
Opin. 26 (2010) 213–222.
[3] P. Naik, P. Murumkar, R. Giridhar, M.R. Yadav, Angiotensin II receptor type 1
(AT1) selective nonpeptidic antagonists—a perspective, Bioorg. Med. Chem. 18
(2010) 8418–8456.
[4] W. White, M. Weber, D. Sica, G. Bakris, A. Perez, C. Cao, S. Kupfer, Effects of the an-
giotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan
on ambulatory and clinic blood pressure in patients with stages 1 and 2 hyperten-
sion, Hypertension 57 (2011) 413–420.
[5] M. De Gasparo, K.J. Catt, T. Inagami, J.W. Wright, Th. Unger, International Union of
Pharmacology. XXIII. The angiotensin II receptors, Pharmacol. Rev. 52 (2000) 415–472.
[6] P. Zoumpoulakis, I. Daliani, M. Zervou, I. Kyrikou, E. Siapi, G. Lamprinidis, E.
Mikros, T. Mavromoustakos, Losartan's molecular basis of interaction with mem-
branes and AT1 receptor, Chem. Phys. Lipids 125 (2003) 13–25.
[7] G. Aggelis, A. Resvani, C. Koukoulitsa, T. Tumonva, J. Slaninova, D. Kalavrizioti, K.
Spyridaki, A. Afantitis, G. Melagraki, A. Siafaka, E. Gkini, G. Megariotis, S.G.
Grdadolnik, M. Papadopoulos, D. Vlahakos, M. Maragoudakis, G. Liapakis, T.
Mavromoustakos, J. Matsoukas, Rational design, efﬁcient syntheses and biological
evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new
class of potent Angiotensin II receptor blockers, Eur. J.Med. Chem. 62 (2013) 352–370.
[8] I.V. Tetko, P. Bruneau, Application of ALOGPS to predict 1-octanol/water distribu-
tion coefﬁcients, logP, and logD, of AstraZeneca in-house database, J. Pharm. Sci.
93 (2004) 3103–3110.
[9] T.R. Oliveira, M.T. Lamy, U.M. De Paula, L.L. Guimarães, M.S. Toledo, H.K.
Takahashi, A.H. Straus, C.J. Lindsey, T.B. Paiva, Structural properties of lipid recon-
structs and lipid composition of normotensive and hypertensive rat vascular
smooth muscle cell membranes, Braz. J. Med. Biol. Res. 42 (2009) 844–853.
[10] M. Lucio, J.L.F.C. Lima, S. Reis, Drug-membrane interactions: signiﬁcance for me-
dicinal chemistry, Curr. Med. Chem. 17 (2010) 1795–1809.
[11] A.M. Seddon, D. Casey, R.V. Law, A. Gee, R.H. Templer, O. Ces, Drug interactions
with lipid membranes, Chem. Soc. Rev. 38 (2009) 2509–2519.
[12] A. Ramamoorthy, Beyond NMR spectra of antimicrobial peptides: dynamical im-
ages at atomic resolution and functional insights, Solid State Nucl. Magn. Reson.
35 (2009) 201–207.677
Please cite this article as: G. Agelis, et al., Interactions of the potent syntheti
silicate matrices, Biochim. Biophys. Acta (2013), http://dx.doi.org/10.1016E
D
 P
R
O
O
F
[13] H. Jerebek, G. Pabst, M. Rappolt, T. Stockner, Membrane-mediated effect on ion
channels induced by the anesthetic drug ketamine, J. Am. Chem. Soc. 132 (2010)
7990–7997.
[14] R.S. Cantor, Lipid composition and the lateral pressure proﬁle in bilayers, Biophys.
J. 76 (1999) 2625–2639.
[15] C. Xing, O.H.S. Ollila, I. Vattulainen, R. Faller, Asymmetric nature of lateral pres-
sure proﬁles in supported lipid membranes and its implications for membrane
protein functions, Soft Matter 5 (2009) 3258–3261.
[16] C. Fotakis, G. Megariotis, D. Christodouleas, E. Kritsi, M. Zervou, P. Zoumpoulakis,
D. Ntountaniotis, C. Potamitis, A. Hodzic, G. Pabst, M. Rappolt, G. Mali, J. Baldus, C.
Glaubitz, M.G. Papadopoulos, A. Afantitis, G. Melagraki, T. Mavromoustakos,
Comparative study of the AT1 receptor prodrug antagonist candesartan cilexetil
with other sartans on the interactions with membrane bilayers, Biochim. Biophys.
Acta 1818 (2012) 3107–3120.
[17] C. Fotakis, D. Christodouleas, P. Zoumpoulakis, E. Kritsi, N.P. Benetis, T.
Mavromoustakos, H. Reis, A. Gili, M.G. Papadopoulos, M. Zervou, Comparative
biophysical studies of sartan class drug molecules losartan and candesartan
(CV-11974) with membrane bilayers, J. Phys. Chem. B 115 (2011) 6180–6192.
[18] C. Potamitis, P. Chatzigeorgiou, E. Siapi, K. Viras, T. Mavromoustakos, A. Hodzic, G.
Pabst, F. Cacho-Nerin, P. Laggner, M. Rappolt, Interactions of the AT1 antagonist
valsartan with dipalmitoyl–phosphatidylcholine bilayers, Biochim. Biophys. Acta
1808 (2011) 1753–1763.
[19] C. Fotakis, D. Christodouleas, P. Chatzigeorgiou, M. Zervou, N.-P. Benetis, K. Viras,
T. Mavromoustakos, Development of a CP 31P NMR broadline simulation meth-
odology for studying the interactions of antihypertensive AT1 antagonist losartan
with phospholipid bilayers, Biophys. J. 96 (2009) 2227–2236.
[20] D. Ntountaniotis, G. Mali, S.G. Grdadolnik, M. Halabalaki, A.-L. Skaltsounis, C.
Potamitis, E. Siapi, P. Chatzigeorgiou, M. Rappolt, T. Mavromoustakos, Thermal,
dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bi-
layers, Biochim. Biophys. Acta 1808 (2011) 2995–3006.
[21] T.M. Mavromoustakos, The use of differential scanning calorimetry to study
drug-membrane interactions, Methods Mol. Biol. 400 (2007) 587–600.
[22] T. Mavromoustakos, P. Chatzigeorgiou, C. Koukoulitsa, S. Durdagi, Partial interdig-
itation of lipid bilayers, Int. J. Quantum Chem. 111 (2011) 1172–1183.
[23] U. Holzgrabe, I. Wawer, B. Diehl, NMR Spectroscopy in Pharmaceutical Analysis,
Elsevier, Amsterdam, 2008.
[24] C. Fotakis, S. Gega, E. Siapi, C. Potamitis, K. Viras, P. Moutevelis-Minakakis, C.G.
Kokotos, S. Durdagi, S. Golic Grdadolnik, B. Sartori, M. Rappolt, T. Mavromoustakos,
Interactions at the bilayer interface and receptor site induced by the novel synthetic
pyrrolidinone analog MMK3, Biochim. Biophys. Acta 1768 (2010) 422–432.
[25] I. Kyrikou, N.P. Benetis, P. Chatzigeorgiou, M. Zervou, K. Viras, C. Poulos, T.
Mavromoustakos, Interactions of the dipeptide paralysin Ala–Tyr and the
aminoacid Glu with phospholipid bilayers, Biochim. Biophys. Acta 1778 (2008)
113–124.
[26] I.W. Levin, R.N. Lewis, Fourier transform Raman spectroscopy of biological mate-
rials, Anal. Chem. 62 (1990) 1101A–1111A.
[27] R.K. Bista, R.F. Bruch, A.M. Covington, Variable-temperature Raman spectro-
microscopy for a comprehensive analysis of the conformational order in PEGylated
lipids, J. Raman Spectrosc. 40 (2008) 463–471.
[28] C.H. Huang, J.R. Lapides, I.W. Levin, Phase-transition behaviour of saturated, sym-
metric chain phospholipid bilayer dispersions determined by Raman spectroscopy:
correlation between spectral and thermodynamic parameters, J. Am. Chem. Soc.
104 (1982) 5926–5930.
[29] D. Zhao, J. Feng, Q. Huo, N. Melosh, G.H. Fredrickson, B.F. Chmelka, G.D. Stucky,
Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 ang-
strom pores, Science 279 (1998) 548–552.
[30] M. Vallet-Regí, F. Balas, D. Arcos, Mesoporous materials for drug delivery, Angew.
Chem. Int. Ed. 46 (2007) 7548–7558.
[31] J.C. Doadrio, E.M.B. Sousa, I. Izquierdo-Barba, A.L. Doadrio, J. Perez-Pariente, M.
Vallet-Regí, Functionalization of mesoporous materials with long alkyl chains
as a strategy for controlling drug delivery pattern, J. Mater. Chem. 16 (2006)
462–466.
[32] A. Bernardos, E. Anzar, C. Coll, R. Martínez-Mañez, J.M. Barat, Ma.D. Marcos, F.
Sancenón, A. Benito, J. Soto, Controlled release of vitamin B2 using mesoporous
materials functionalized with amine-bearing gate-like scaffoldings, J. Control.
Release 131 (2008) 181–189.
[33] Q. Yang, S. Wang, P. Fan, L. Wang, Y. Di, K. Lin, F.S. Xiao, pH-responsive carrier sys-
tem based on carboxylic acid modiﬁed mesoporous silica and polyelectrolite for
drug delivery, Chem. Mater. 17 (2005) 5999–6003.
[34] S. Giri, B.G. Trewyn, M.P. Stellmaker, V.S.Y. Lin, Stimuli-responsive controlled re-
lease delivery system based on mesoporous silica nanorods capped with magnetic
nanoparticles, Angew. Chem. Int. Ed. 44 (2005) 5038–5044.
[35] A. Sayari, B.-H. Han, Y. Yang, Simple synthesis route to monodispersed SBA-15 sil-
ica rods, J. Am. Chem. Soc. 126 (2004) 14348–14349.
[36] T. Ukmar, A. Godec, O. Planinšek, V. Kaučič, G. Mali, M. Gaberšcek, The phase
(trans)formation and physical state of a model drug in mesoscopic conﬁnement,
Phys. Chem. Chem. Phys. 13 (2011) 16046–16054.
[37] T. Ukmar, T. Čendak, M. Mazaj, V. Kaučič, G. Mali, Structural and dynamical prop-
erties of indomethacin molecules embedded within the mesopores of SBA-15: a
solid-state NMR view, J. Phys. Chem. C 116 (2012) 2662–2671.
[38] X. Tian, S. Pavlopoulos, Y. De-Ping, A. Makriyannis, The interaction of cannabinoid
receptor agonists, CP55940 and WIN55212-2 with membranes using solid state 2H
NMR, Biochim. Biophys. Acta 1808 (2011) 2095–2101.c AT1 antagonist analog BV6withmembrane bilayers andmesoporous
/j.bbamem.2013.03.009
